Impact Factor
3.04
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.08
341 total citations
h5-index
22
h5 depth signal
Cited share
63.3%
112 of 177
Total citations
341
Citation footprint
Metric signal
1.76
External metric anchor
Self-citation
5.9%
20 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
427
United Kingdom
169
Germany
90
Switzerland
87
Japan
62
Citing Fields of Research
Statistical Methods
758
Medical Ethics
102
Clinical Laboratory Science
30
Pharmacology & Toxicology
30
Oncology
28
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,644
Articles tracked across the journal lifetime
Indexed publication set
177
112 cited publications
Last 12 months
89
7.4 publications/month
Open access share
32.6%
29 OA publications in the last year
Leading citing country
United States
427 citing publications
Leading citing field
Statistical Methods
758 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v5n1, Jan./Mar. 2006-
v5n1, Jan./Mar. 2006-
Research Focus & Classification
Indexed Subjects
Statistical Methods
Issuing & Sponsoring Bodies
Contributor
Statisticians in the Pharmaceutical Industry (Organization)
Broad Categories
Pharmacology
Statistics as Topic
Statistical Methods
MeSH Descriptors
Drug Industry
Statistics as Topic
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1002/pst.70126
Open DOI
Joint Model for Assessing the Effect of Frailty and Longitudinal Measures in Time‐To‐Event Outcome
Joint modeling provides a robust statistical framework for simultaneously modeling longitudinal covariate and time‐to‐event outcome. Apart from the interdependence between longitudinal and survival outcomes there may exist some unobserve...
02
DOI 10.1002/pst.70135
Open DOI
Variable Selection for the Propensity Score Model: Beyond Main Effects and Linear Relations
Propensity score methods are frequently used to estimate treatment effects in observational studies. The propensity score is usually estimated using a logistic regression model with additive and linear effects. The limited literature on ...
03
DOI 10.1002/pst.70136
Open DOI
Variations of Power Priors in Time‐to‐Event Analysis With Piecewise Constant Hazards Through Baseline and Outcome Similarity Driven Bounded Weighting
Patient recruitment in clinical trials, particularly in rare diseases or pediatric populations, remains a significant challenge. Leveraging external data to supplement trial information offers a promising solution, reducing placebo alloc...
04
DOI 10.1002/pst.70132
Open DOI
Power With Confounders in Clinical Trials Using External Controls
When the number of patients is limited in clinical trials for rare diseases and pediatric developments, enrolling sufficient participants for confirmatory randomized clinical trials is difficult. Alternative trial designs using external ...
05
DOI 10.1002/pst.70134
Open DOI
Multiple Imputation for Recurrent Events With Off‐Risk Periods
When observation of recurrent events ends before the planned follow‐up time, conclusions may depend on untestable assumptions about outcomes during the unobserved period. This is especially challenging for recurrent outcomes such as hosp...
06
DOI 10.1002/pst.70133
Open DOI
BOIN12 ‐ PFS : A Bayesian Optimal Interval Phase I / II Design Incorporating Progression‐Free Survival Endpoint
Modern oncology drug development is increasingly focused on identifying the optimal biological dose (OBD) rather than just the maximum tolerated dose (MTD). Early‐phase oncology trials have conventionally relied on short‐term endpoints, ...
07
DOI 10.1002/pst.70120
Open DOI
TITE ‐ LOCRM12 : A Local Continual Reassessment Method for Drug Combination Optimization Based on Late‐Onset Toxicity and Efficacy Outcomes
The primary goal of Phase I/II combination trials is to identify the optimal biological dose combination (OBDC), defined as the dose combination that achieves the highest efficacy while maintaining an acceptable toxicity rate. Several de...
08
DOI 10.1002/pst.70129
Open DOI
A Practical Guide to Optimal Adaptive Two‐Stage Designs for Various Endpoint Types
Adaptive designs are frequently used to adjust sample sizes based on interim data, ensuring reliable conclusions while protecting resources. To maximize trial efficiency, design parameters can be optimized to minimize an objective functi...
09
DOI 10.1002/pst.70127
Open DOI
BEACON : An Adaptive Bayesian Early‐Phase Oncology Trial Design Integrating Dose Optimization and Proof‐of‐Concept Across Survival and Binary Endpoints
Conventional dose selection in oncology, which focuses on the maximum tolerated dose (MTD), has certain limitations for targeted agents and immunotherapies, where the efficacy‐toxicity relationship may not be monotonic. Regulatory initia...
10
DOI 10.1002/pst.70130
Open DOI
On the Conservativeness of Robust Variance Estimators in Propensity Score Weighted Cox Models
In propensity score weighted analysis, robust variance that does not account for weight estimation (hereafter, uncorrected variance) is commonly used. In propensity score weighted Cox models (CoxPSW), the uncorrected variance is known to...
Bibliographical & Catalog Notes
Title from cover.
Latest issue consulted: Vol. 3, no. 1 (Jan./Mar. 2004).
Print issues ceased with v. 13 (2014).
Also issued online.
Journal of Statisticians in the Pharmaceutical Industry.
v. 1, no. 1 (June 2002)20070104 Notice published Printed on acid-free paper